Summary Effective radioimmunotherapy is limited by slow antibody clearance from the circulation, which results in low tumour to blood ratios and restricts the dose of radiolabelled anti-tumour antibody that can be safely administered. Avidin and streptavidin clearing agents have been shown to effectively complex and clear radioactive biotinylated antibodies from the circulation, but their immunogenicity may limit their repeated use. We have investigated whether polyethylene glycol (PEG) modification can reduce the immunogenicity of our galactosylated streptavidin (gal-streptavidin) clearing agent without altering its effectiveness as a clearing agent. The immune response evoked in mice after intraperitoneal injection of 30 ,g of gal-streptavidin was decreased after PEG modification, as shown by lower antibody titres and a reduction in the number of mice that elicited an anti-gal-streptavidin response. The effect of PEG-modified gal-streptavidin on the blood clearance and tumour localisation of a "5I-labelled biotinylated anti-CEA was investigated in the LS174T human colon carcinoma xenograft in nude mice. Although PEG modified gal-streptavidin bound the ['25I]biotinylated antibody in vivo, effective clearance from the circulation was inhibited, resulting in very little reduction in the levels of circulating radioactivity, together with a decrease in the antibody localised to the tumour.
Avidin and streptavidin have frequently been used in various clearance and pretargeting strategies with a view to increasing the low tumour to blood ratios usually observed with radioimmunotargeting of tumours. Both avidin and streptavidin are efficient clearing agents for radiolabelled biotinylated antibodies, reducing the amount of radioantibody that normally persists in the circulation (Sinitsyn et al., 1989; Paganelli et al., 1990a) . This results in significantly higher tumour to blood ratios (Marshall et al., 1994) , which are essential to reduce the risk of myelotoxicity while still allowing effective radioimmunotherapy. The streptavidinbiotinylated antibody complexes are cleared via the reticuloendothelial system, although persistent radioactivity in the spleen has been noted (Marshall et al., 1994) . A galactosylated form of streptavidin has recently been shown to direct clearance of the complexes to the asialoglycoprotein receptor of the liver, thus avoiding the accumulation of damaging radiation in the spleen (Marshall et al., 1995) .
Pretargeting strategies using streptavidin or avidin either as the carrier of the radioisotope to a tumour pretargeted with biotinylated antibody (Paganelli et al., 1992; Khawli et al., 1993; Saga et al., 1994) or as the clearing agent for biotinylated antibodies before administration of the radioisotope in three-step pretargeting (Paganelli et al., 1990b (Paganelli et al., , 1991a have also been described as successfully reducing the blood background levels of radioactivity.
These avidin-biotin strategies are now moving forward into the clinic where the immunogenicity of avidin and streptavidin has been noted (Paganelli, 1991a (Paganelli, ,b, 1992 and which may limit their use in repeated therapy. The immunogenicity of murine monoclonal antibodies has been a constant hindrance to antibody-directed therapy of tumours, causing hypersensitivity reactions and also accelerated clearance of the antibody from the circulation, rendering the therapeutic antibody ineffective. The production of antimouse antibodies can be controlled to some extent by immunosuppressive drugs, for example Cyclosporin A (Ledermann et al., 1988) , although general immunosuppression of patients is undesirable. To overcome the problem of immunogenicity of murine antibodies, chimeric antibodies constructed from the variable regions of the mouse antibody together with human constant regions have been produced and have shown reduced immunogenicity in man (LoBuglio et al., 1989) , as have humanised antibodies constructed from only the hypervariable complementarity-determining regions (CDRs) of the mouse antibody built into the framework of a human antibody (Hale et al., 1988; Hird et al., 1991) .
For proteins that cannot be substituted with a human equivalent, the problem of immunogenicity can be tackled by polyethylene glycol (PEG) conjugation. PEG has been covalently linked to many different proteins, after which an increased half-life and a reduction in immunogenicity has been reported (Abuchowski et al., 1977; Lee and Sehon, 1977; Kamisaki et al., 1981; Katre, 1990) , although often with a concomitant reduction in the activity of the proteins (Kamisaki et al., 1981; Kitamura et al., 1991; Tsutsumi et al., 1995) .
In this paper we describe an investigation into whether the conjugation of PEG to our galactosylated streptavidin (galstreptavidin) clearing agent would reduce its immunogenicity, while still allowing effective clearance of an anti-tumour antibody. Immunocompetent mice were immunised with galstreptavidin conjugated with different amounts of PEG and their serum was tested for anti-gal-streptavidin antibodies. The effect of PEG modification on the ability of galstreptavidin to complex and clear ['25I ]biotinylated A5B7, a murine monoclonal anti-CEA antibody, was investigated in nude mice bearing the LS 174T human colon carcinoma xenograft.
Materials and methods Preparation of PEG gal-streptavidin Galactose conjugation Streptavidin was galactosylated as previously described (Marshall et al., 1995) . Briefly, 0.1 M cyanomethyl -2,3,4,6 -tetra -O-acetyl-1-thio-, -D-galactopyranoside in dry methanol was mixed with 10% of 0.1 M sodium methoxide and allowed to stand for 48 h. Approximately 5.6 ml of this galactopyranoside solution was evaporated to Correspondence: D Marshall dryness in a round-bottomed flask, to which 37 mg of streptavidin (10 mg ml-' in 25 mm sodium borate, pH 8.5) was added. After 2 h the galactosylated streptavidin was then purified by gel filtration on Sephadex G25 (Pharmacia, Uppsala, Sweden) and carbohydrate content assayed by the phenol-sulphuric acid method of Dubois et al. (1956) , using a galactose standard. The streptavidin was found to contain 54 pg of galactose per mg of streptavidin.
Polyethylene glycol conjugation PEG was conjugated to galstreptavidin using PEG-maleimide by the method of Pedley et al. (1994) . To make the maleimide derivative, 10 mM methoxypolyoxyethylene amine (approximate mol.wt. = 5000, Sigma, Poole, UK) was dissolved in 0.1 M sodium phosphate, pH 7.0 and incubated with 1.2 M excess of 200 mM 3-maleimidopropionic acid N-hydroxysuccinimide ester (Sigma) dissolved in N,N-dimethylformamide (Fluka, Gillingham, UK) for 30 min at room temperature. An aliquot of the reaction mixture was spotted onto a thinlayer chromatography plate, developed with ninhydrin (Fisons, Loughborough, UK) and the reaction was considered complete when no purple coloration could be detected (i.e. no amine groups remained). The mixture was then applied to a Sephadex G25 column (Pharmacia), and the PEG-maleimide was eluted with deionised water, lyophilised and stored in a desiccator at 4°C until used.
The PEG-maleimide reacts with thiol groups that were incorporated into gal-streptavidin by the method of Turner et al. (1994) . The gal-streptavidin was first dialysed into 0.1 M sodium hydrogen carbonate, pH 8.0, containing 2 mM EDTA. A 10-or 20-fold molar excess of 2-iminothiolane (Traut's reagent, Pierce and Warriner, Chester, UK) was added and the reaction mixture incubated for 1 h at 37°C. After gel filtration on Sephadex G25 to remove unreacted Traut's reagent the average number of thiols per molecule of streptavidin was determined by titration with 4,4'-dithiodipyridine (Sigma) (Lyons et al., 1990) . PEG-maleimide was added to the thiolated gal-streptavidin at a five times molar excess over the thiols and incubated for 1 h at 37°C. Any unreacted PEG-maleimide was removed by gel filtration on Sephadex G25, the number of thiol groups remaining was assessed and therefore the number of PEG molecules successfully conjugated could be determined. Gal-streptavidin with an average of 2.5 or 5 molecules of PEG per galstreptavidin molecule resulted, which were finally dialysed into phosphate-buffered saline (PBS), pH 7.4. The protein concentration of the PEG-modified gal-streptavidin was calculated from the absorbance at 280 nm and is a measure of the protein component of the molecule only, as PEG does not absorb at 280 nm. To assess the apparent molecular weight of PEG gal-streptavidin the protein was radiolabelled with 125I by the Iodo-gen method (Fraker and Speck, 1978) for 20 min (to a specific activity of 1 pCi pg-') and then applied to a 110 cm x 1 cm Sephacryl S300 gel filtration column (Pharmacia 24 and 48 h after injection of the clearing agents) were applied to a 110 cm x 1 cm Sephacryl S300 gel filtration column and 1.3 ml fractions counted for 1251 radioactivity in a multiwell gamma-counter.
Results
Preparation of PEG-modified gal-streptavidin Figure 1 shows the effect of PEG modification on the apparent molecular weight of gal-streptavidin as assessed by gel filtration on a Sephacryl S300 column. 5 PEG galstreptavidin, with a higher apparent molecular weight than unmodified gal-streptavidin, eluted earliest with a peak at fraction number 37 (48.1 ml), 2.5 PEG gal-streptavidin eluted slightly later with a peak at fraction 40 (52 ml), whereas galstreptavidin had a peak at fraction number 46 (59.8 ml). The void volume of the column was found to be 37.7 ml (as assessed by the elution of blue dextran at fraction 29). The broad elution peaks of the PEG-modified gal-streptavidin samples indicated that different sized molecules were present in each preparation. This was to be expected, as the PEG reagent is comprised of different molecular weight molecules (average mol.wt. = 5000) and 2.5 PEG and 5 PEG refers only to an average number of PEG molecules conjugated to galstreptavidin. If the apex of the peak is used to calculate the average molecular weight of the protein, then values of approximately 188 000 and 326 000 are obtained for 2.5 PEG and 5 PEG gal-streptavidin respectively, which are higher than the expected molecular weight of the proteins. This is thought to be due to the random coil structure of the PEG, which produces a much larger increase in the hydrodynamic radius of the protein than expected from the molecular mass alone (Delgado et al., 1992) . In vitro biotin binding of gal-streptavidin was impaired after PEG modification as shown by ELISA (Figure 2 ). However, this assay also indicates that the PEG-modified galstreptavidin must still have at least two functional biotinbinding sites, since it was sandwiched between biotinylated antibody bound to the CEA wells and the biotin peroxidase used in the final stage of the assay.
Immunogenicity studies The effect of PEG modification on the immunogenicity of gal-streptavidin is shown in Figure 3 . The anti-gal\ streptavidin response in each mouse is expressed as a percentage of a positive control antibody standard. Figure  3a shows gal-streptavidin to be immunogenic in mice, with mice eliciting an anti-gal-streptavidin response in the range of 1.0-2.1% of the control 14 days after the primary injection, increasing to 7.5-91.7% and 24.4-156% of the control 7 and 14 days after the boost injection of gal-streptavidin (21 and 28 days after primary injection). Mice injected with 2.5 PEG gal-streptavidin (Figure 3b) showed a range in anti-galstreptavidin response of 0-7.2% of the control antibody 14 days after primary immunisation, and although the anti-gal- .n b ::~~Fraction number Figure 1 Effect of PEG modification on the apparent molecular weight of gal-streptavidin as assessed by gel filtration on Sephacryl S300. *, gal-streptavidin; 0, 2.5 PEG gal-streptavidin; fC, 5 PEG gal-streptavidin. Markers for the void volume, 669 kDa and 200 kDa were also applied to the column. gal-streptavidin clearing agent resulted, as expected, in a rapid decrease in blood radioactivity from 13.6% ID/g to 3.6% ID/g, with the gal-streptavidin-biotinylated antibody complexes being cleared through the liver. Twenty-four hours after administration of 2.5 PEG galstreptavidin ( Figure 4b ) the level of radioactivity in the blood was again similar to the control animals without any clearing agent. By this time point though, a reduction in tumour radioactivity from 24.4% ID/g to 14.3% ID/g was observed, thus resulting in a tumour to blood ratio of only 2.0+0.13. The effect of administration of unmodified gal-streptavidin on the biodistribution of ['251I]biotinylated A5B7 is shown in comparison, and although a reduction in antibody localised at the tumour was also observed (from 24.4% ID/g to 12.5% ID/g), the increased blood clearance to only 0.8% ID/ g resulted in an improved tumour to blood ratio of 16.7 + 5.3. Figure 4c shows that by 48 h after injection of 2.5 PEG gal-streptavidin a reduction in blood radioactivity was noted (from 7.6% ID/g to 2.4% ID/g), although this was not as great as that seen after administration of the unmodified galstreptavidin (0.28% ID/g). A similar decrease in tumour radioactivity was also observed after administration of 2.5 PEG gal-streptavidin, therefore resulting in no improvement in the tumour to blood ratio (2.5 + 1.2 compared with 3.8 + 2.2 in control animals without administration of clearing agent), whereas the unmodified gal-streptavidin gave an improved tumour to blood ratio of 29.7+14.4 (range 16.9 to 48.8).
5 PEG-modified gal-streptavidin 5 PEG gal-streptavidin had no effect on the biodistribution of ['25I]biotinylated A5B7 1 h after administration, whereas unmodified gal-streptavidin reduced the level of circulating ['251]biotinylated A5B7 3.3-fold from 15.5% ID/g in the controls to 4.7% ID/g ( Figure  Sa ).
By 24 hours there was still little difference between the radioactivity levels in the circulation of control animals and those injected with S PEG gal-streptavidin clearing agent (Figure 5b ), but tumour levels of the latter were reduced by half to 16.6% ID/g, resulting in a poor tumour to blood ratio of 1.5 + 0.8 compared with 2.5 + 1.0 in antibody alone control animals. Clearance with unmodified gal-streptavidin gave a corresponding tumour to blood ratio of 29.6+23.5 (range from 9.9 to 63.2).
A similar pattern was again seen 48 h after administration of the clearing agents (Figure 5c Fracbton number Figure 6 Analysis of serum by gel filtration on Sephacryl S300 24 h after administration of 2.5 PEG gal-streptavidin (0) There is great interest in the development of a clearing agent that is also non-immunogenic and therefore an investigation to reduce the immunogenicity of our gal-streptavidin clearing agent (Marshall et al., 1995) was undertaken.
Polyethylene glycol (PEG) is a linear, water-soluble, uncharged, flexible polymer that is available in various molecular weights and can be readily conjugated to proteins. PEG conjugation has been reported to abolish or reduce the immunogenicity of many proteins and was therefore an ideal candidate in an attempt to reduce the immunogenicity of our gal-streptavidin clearing agent.
The conjugation of PEG to gal-streptavidin was found to decrease its immunogenicity in mice (Figure 3 ). Anti-galstreptavidin antibody titres after injection of 2. (1990) who noted that only three out of ten rabbits mounted an immune response to PEG-IL2, compared with ten out of ten immunised with unmodified interleukin 2 (IL-2), and did so later than those injected with IL-2. It was also noted that an increase in the degree of PEG modification further reduced the immunogenicity of the IL-2 protein in mice, as found with our PEG gal-streptavidin. It has been reported that tolerance can be induced in mice after immunisation with PEG-conjugated proteins, depending on the degree of PEG modification and dose of PEG protein (Savoca et al., 1984) . Wilkinson et al. (1987a) found an approximately 80% reduction in the antibody response to human IgG if PEG-human IgG had been injected 6-43 days before, and it has also been reported that induced tolerance can be transferred to naive mice by T cells and T cell extracts (Wilkinson et al., 1987b) . It may be possible to induce tolerance to gal-streptavidin with PEG gal-streptavidin, as indicated by the two mice that failed to show any immune response to gal-streptavidin after prior injection of 5 PEG gal-streptavidin, although a full investigation with more animals is needed to confirm this finding.
Loss in bioactivity after PEG modification has been frequently noted for many proteins. Although increasing the number of PEG molecules per gal-streptavidin also reduced the immunogenicity, this increase in PEG conjugation also resulted in a significant decrease in biotin binding of the gal-streptavidin when tested by ELISA (Figure 2 ). Increasing the degree of PEG modification has been reported by others to result in a decrease in the bioactivity of the protein (Wieder et al., 1979; Kitamura et al., 1991; Tsutsumi et al., 1995) and although early PEG modification methods were particularly harsh, protein inactivation has been reduced by using different conjugation methods (Abuchowski et al., 1984) . Several reasons for the reduction in bioactivity after PEG modification have been proposed, including conjugation of PEG to residues that are vital for the reactivity of the protein (Wieder et al., 1979; Veronese, 1994) . This is unlikely to be the reason for the loss in biotin binding after PEG conjugation to galstreptavidin, as the PEG was linked via lysine residues that are not considered to be involved in the biotin binding process of streptavidin (Wilchek and Bayer, 1989 (1987) found that alkaline phosphatase conjugated with low molecular weight PEG had greater activity than when modified to the same degree of lysine substitution but with higher molecular weight PEG, indicating that the long chain of the polymer itself sterically hinders the substrate from binding to the active site. Both forms of PEG gal-streptavidin were tested to assess whether their ability to complex and clear [125I] biotinylated antibodies from the circulation had been altered. One hour after gal-streptavidin injection neither the 2.5 nor the 5 PEG gal-streptavidin had reduced the circulating radioactivity, whereas unmodified gal-streptavidin had reduced the blood radioactivity by approximately 3-fold. It has been suggested that PEG-modified proteins are slower in their diffusion from a subcutaneous injection site than unmodified proteins (Dreborg and Akerblom, 1990) and therefore the lack of blood clearance at this early time point was initially thought to be due to PEG gal-streptavidin taking longer to gain access to the blood stream from the peritoneal cavity.
The results obtained 24 h after PEG gal-streptavidin were rather surprising in that, although blood radioactivity levels were similar to the control animals without clearing agent, the tumour levels were reduced significantly (1.7-fold and 2-fold reduction after 2.5 and 5 PEG gal-streptavidin 571 respectively). A similar finding was observed 48 h after administration of the 5 PEG molecule and, although blood radioactivity levels after injection of the 2.5 PEG galstreptavidin were less than the control animals with ['25I]biotinylated A5B7 alone, the low levels of radioactivity in the tumour resulted in a tumour to blood ratio of only 2.5 + 1.2 compared with a tumour to blood ratio of 29.7+14.4 after administration of unmodified gal-streptavidin. The gel filtration of the serum at these later time points after PEG gal-streptavidin administration (Figure 6 ) indicated that the activity in the blood was circulating as a high molecular weight complex. Therefore, although the biotin binding of PEG gal-streptavidin was inhibited in vitro, the PEG modified gal-streptavidin was still able to bind to the [1251]biotinylated A5B7 in vivo sufficiently to form large radiolabelled complexes (as shown by the shift in the peak of radioactivity from fraction 42, as expected for
[1251I]biotinylated A5B7, to elution in the void volume of the column). PEG modified proteins are known to have an extended half-life in vivo (Kamisaki et al., 1981; Tsutsumi et al., 1995) irrespective of whether the usual pattern of clearance is via the reticuloendothelial system, is receptormediated carbohydrate recognition, or passive excretion (Beauchamp et al., 1983) . PEG is thought to act as a shield around the protein that protects it from elimination from the body, making clearance slower without changing the route of clearance, as shown by competition experiments of Beauchamp et al. (1983) . Therefore, it appears that even though the ['251 ]biotinylated antibody was part of a high molecular weight complex that would normally be cleared rapidly from the body via asialoglycoprotein receptors in the liver, the PEG component of the PEG gal-streptavidin-bound
[1251]biotinylated antibody prevented its rapid removal from the circulation, presumably by masking receptor recognition.
The radioactivity at the tumour site is thought to be maintained at a high level if the blood levels of the radiolabelled antibody are also high, due to the existence of an equilibrium between bound and non-bound, circulating antibody. Therefore, rapid removal of circulating antibody after administration of a clearing agent disrupts this equilibrium, resulting in reduced levels of antibody associated with the tumour (Sharkey et al., 1988 (Sharkey et al., ,1992 . In this present study, it appears that the radiolabelled antibody was present in the circulation only as part of a high molecular weight complex, not as free [1251I]biotinylated antibody. Therefore, the antibody would be inhibited from binding at the tumour site. Any equilibrium between tumour-bound and circulating antibody would be disrupted and any antibody that dissociated from the tumour or was shed with the tumour antigen would not be replenished, therefore, although radioactivity was still elevated in the circulation after PEG gal-streptavidin, the high levels of radioactivity at the tumour site could not be maintained.
In conclusion, while the immunogenicity of a streptavidin clearing agent can be successfully reduced by conjugation with PEG, this advantage is compromised by the slow clearance of the subsequent PEG gal-streptavidin-biotinylated antibody complexes, which results in very limited reduction in the level of damaging radioactivity circulating in the blood, while also reducing tumour accumulation. PEG modification is very appealing for many non-human proteins used in the clinic, but the use of PEG for decreased immunogenicity of an antibody clearing agent is clearly limited. Preliminary data suggests that PEG gal-streptavidin could make the mice tolerant to the unmodified clearing agent. PEG proteins have previously been implicated as tolerogens in mice and, although this is an attractive use for PEG-modified gal-streptavidin, the ability of PEG-modified proteins to induce tolerance in man is yet to be tested. The gal-streptavidin used in this series of experiments had relatively low amounts of galactose compared with previous gal-streptavidin clearing agents that have been used. It may be possible that if the degree of galactosylation was increased, then faster clearance via the asialoglycoprotein receptor may still be possible even after PEG conjugation and this is under investigation.
